{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:16:40Z","timestamp":1793953000501,"version":"4.8.0"},"reference-count":35,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Strategic Research and Innovation Plan for Health","award":["grant number SLT021\/21\/000022"],"award-info":[{"award-number":["grant number SLT021\/21\/000022"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,7,21]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Women with recurrent urinary tract infections (UTIs) often undergo intensive antibiotic exposure, especially with suppressive therapies. Suppressive therapy is recommended for women with three UTIs in the past year or two in the last 6\u2009months. However, the collateral long-term effects of this have been poorly studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess whether suppressive therapy for recurrent UTIs increases the incidence and severity of future infections compared with episodic UTI treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting and Participants<\/jats:title>\n                    <jats:p>The study was conducted using data from the Information System for Research in Primary Care database, including 5.8\u2009million people in Catalonia. Two groups of women with recurrent UTIs (\u22653 episodes\/year) were compared: those on suppressive antibiotic therapy for \u22656 months and those treated episodically. Primary outcomes were hospitalisations due to pyelonephritis, septicaemia, COVID-19, influenza, pneumonia and mortality by these infections, over a 100-month follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 36\u2009170\u2009women, 2898 (8%) were treated with continuous suppressive therapy. Overall, 6.9% of the population experienced severe infections, with a higher incidence in women on suppressive therapy (12.6%) compared with those without (6.4%), with a HR of 1.50 (95% CI 1.33 to 1.68). Pyelonephritis presented the greatest difference (HR, 1.95 (95% CI 1.64 to 2.33)), followed by septicaemia (HR, 1.34 (95% CI 1.13 to 1.59)) and COVID-19 (HR 1.23 (95% CI 1.01 to 1.50)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Suppressive antibiotic therapy in women with recurrent UTIs is associated with a higher incidence and severity of future infections. Future research should focus on clarifying causal relationships and identifying the potential mechanisms involved.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-098371","type":"journal-article","created":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T07:30:19Z","timestamp":1755415819000},"page":"e098371","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Exposure to suppressive antibiotic therapy in women with recurrent urinary tract infections and severity of infections: a retrospective population-based cohort study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6644-717X","authenticated-orcid":false,"given":"Carl","family":"Llor","sequence":"first","affiliation":[{"name":"IDIAP Jordi Gol, Barcelona, Spain"},{"name":"CIBER Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Department of Public Health, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8630-152X","authenticated-orcid":false,"given":"Dan","family":"Ouchi","sequence":"additional","affiliation":[{"name":"IDIAP Jordi Gol, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Fern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"IDIAP Jordi Gol, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-9233","authenticated-orcid":false,"given":"Maria","family":"Giner-Soriano","sequence":"additional","affiliation":[{"name":"Medicines Research Unit, IDIAP Jordi Gol, Barcelona, Catalunya, Spain"},{"name":"Universitat Aut\u00f2noma de Barcelona, Bellaterra (Cerdanyola del Vall\u00e8s), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Moragas","sequence":"additional","affiliation":[{"name":"Primary Healthcare Centre Jaume I, Tarragona, Spain, Universitat Rovira i Virgili, Tarragona, Catalunya, Spain"},{"name":"CIBER Enfermedades Infecciosas, IDIAP Jordi Gol, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Morros","sequence":"additional","affiliation":[{"name":"Medicines Research Unit, IDIAP Jordi Gol, Barcelona, Catalunya, Spain"},{"name":"Departament de Farmacologia i Terap\u00e8utica, Universitat Autonoma de Barcelona Facultat de Medicina, Bellaterra, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"2025123106463180000_15.8.e098371.1","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2016.91","article-title":"Embracing the gut microbiota: the new frontier for inflammatory and infectious diseases","volume":"6","author":"van den Elsen","year":"2017","journal-title":"Clin & Trans Imm"},{"key":"2025123106463180000_15.8.e098371.2","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1007\/s10238-023-01171-5","article-title":"Is there a correlation between antibiotic use and the severity or post-infection conditions of COVID-19 and other viral infections?","volume":"23","author":"Au","year":"2023","journal-title":"Clin Exp Med"},{"key":"2025123106463180000_15.8.e098371.3","doi-asserted-by":"crossref","unstructured":"Llor C , Ouchi D , Giner-Soriano M , et al . n.d. Correlation between Previous Antibiotic Exposure and COVID-19 Severity. A Population-Based Cohort Study. Antibiotics (Basel) 10:1364. doi:10.3390\/antibiotics10111364","DOI":"10.3390\/antibiotics10111364"},{"key":"2025123106463180000_15.8.e098371.4","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1035422","article-title":"Gut microbiota profile of COVID-19 patients: Prognosis and risk stratification (MicroCOVID-19 study)","volume":"13","author":"Nobre","year":"2022","journal-title":"Front Microbiol"},{"key":"2025123106463180000_15.8.e098371.5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/14787210.2024.2303019","article-title":"Predictors and patterns of empirical antibiotic therapy and associated outcomes in COVID-19 patients: a retrospective study in a tertiary care facility in South India","volume":"22","author":"Lukose","year":"2024","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025123106463180000_15.8.e098371.6","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics13060566","article-title":"Exploring Prior Antibiotic Exposure Characteristics for COVID-19 Hospital Admission Patients: OpenSAFELY","volume":"13","author":"Yang","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"2025123106463180000_15.8.e098371.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102064","article-title":"Repeated antibiotic exposure and risk of hospitalisation and death following COVID-19 infection (OpenSAFELY): a matched case-control study","volume":"61","author":"Yang","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025123106463180000_15.8.e098371.8","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics11070847","article-title":"Antibiotic (Mis)Use in COVID-19 Patients before and after Admission to a Tertiary Hospital in Serbia","volume":"11","author":"Despotovi\u0107","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2025123106463180000_15.8.e098371.9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1019378108"},{"key":"2025123106463180000_15.8.e098371.10","first-page":"304","article-title":"Antiviral immunity: Flora against the flu","volume":"11","author":"Papatriantafyllou","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"2025123106463180000_15.8.e098371.11","unstructured":"Bonkat G , Kranz J , Cai T , et al . European Association of Urology Guidelines on Urological Infections: 2025 Guidelines, Available: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Urological-infections-2025.pdf"},{"key":"2025123106463180000_15.8.e098371.12","unstructured":"Gu\u00eda multidicsiplinar . Asociaci\u00f3n Espa\u00f1ola de Urolog\u00eda. Cistitis no complicada en la mujer, 2013. Available: https:\/\/portal.guiasalud.es\/wp-content\/uploads\/2018\/12\/GPC_530_Cistitis_complicada_mujer_2013.pdf"},{"key":"2025123106463180000_15.8.e098371.13","unstructured":"JF CP , J GB , eds. In: Atenci\u00f3n Primaria, Principios, organizaci\u00f3n y m\u00e9todos en Medicina de Familia. Barcelona: Elsevier Espa\u00f1a, n.d.: 856\u201392."},{"key":"2025123106463180000_15.8.e098371.14","unstructured":"SIDIAP . SIDIAP Information system for research in Primary Care (SIDIAP), 2024. Available: http:\/\/www.sidiap.org\/index.php\/en"},{"key":"2025123106463180000_15.8.e098371.15","unstructured":"World health organization . In: International Statistical Classification of Diseases and Related Health Problems 10th Revision. 2016. Available: https:\/\/apps.who.int\/iris\/handle\/10665\/246208"},{"key":"2025123106463180000_15.8.e098371.16","unstructured":"World Health Organization . Collaborating Centre for Drug Statistics Methodology. ATC\/DDD Index 2024, 2024. Available: https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/methodology\/"},{"key":"2025123106463180000_15.8.e098371.17","unstructured":"CatSalut . Servei catal\u00e0 de la salut. In: Conjunt m\u00ednim b\u00e0sic de dades (CMBD). 2023. Available: http:\/\/catsalut.gencat.cat\/ca\/proveidors-professionals\/registres-catalegs\/registres\/cmbd\/"},{"key":"2025123106463180000_15.8.e098371.18","doi-asserted-by":"publisher","DOI":"10.1157\/13123961"},{"key":"2025123106463180000_15.8.e098371.19","doi-asserted-by":"publisher","DOI":"10.1016\/J.APRIM.2016.06.003"},{"key":"2025123106463180000_15.8.e098371.20","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro.2017.14"},{"key":"2025123106463180000_15.8.e098371.21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature10213","article-title":"Human nutrition, the gut microbiome and the immune system","volume":"474","author":"Kau","year":"2011","journal-title":"Nature New Biol"},{"key":"2025123106463180000_15.8.e098371.22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-30504-3","article-title":"A multicentre study reveals dysbiosis in the microbial co-infection and antimicrobial resistance gene profile in the nasopharynx of COVID-19 patients","volume":"13","author":"Mahmud","year":"2023","journal-title":"Sci Rep"},{"key":"2025123106463180000_15.8.e098371.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.gpb.2014.06.001"},{"key":"2025123106463180000_15.8.e098371.24","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.596166","article-title":"Viral Infections, the Microbiome, and Probiotics","volume":"10","author":"Harper","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"2025123106463180000_15.8.e098371.25","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1017\/S0007114521001926","article-title":"Beyond probiotic legend: ESSAP gut microbiota health score to delineate SARS-COV-2 infection severity","volume":"127","author":"Hegazy","year":"2022","journal-title":"Br J Nutr"},{"key":"2025123106463180000_15.8.e098371.26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-85750-0","article-title":"Functional profiling of COVID-19 respiratory tract microbiomes","volume":"11","author":"Haiminen","year":"2021","journal-title":"Sci Rep"},{"key":"2025123106463180000_15.8.e098371.27","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-019-1394-6","article-title":"Antibiotic use and the risk of rheumatoid arthritis: a population-based case-control study","volume":"17","author":"Sultan","year":"2019","journal-title":"BMC Med"},{"key":"2025123106463180000_15.8.e098371.28","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S2666-5247(22)00355-X","article-title":"Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis","volume":"4","author":"Langford","year":"2023","journal-title":"Lancet Microbe"},{"key":"2025123106463180000_15.8.e098371.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33395-6"},{"key":"2025123106463180000_15.8.e098371.30","doi-asserted-by":"publisher","DOI":"10.1038\/ismej.2015.99"},{"key":"2025123106463180000_15.8.e098371.31","article-title":"Antibiotics for preventing recurrent urinary tract infection in non-pregnant women","volume":"2004","author":"Albert","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"2025123106463180000_15.8.e098371.32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015233","article-title":"Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: systematic review and meta-analysis of randomised trials","volume":"7","author":"Ahmed","year":"2017","journal-title":"BMJ Open"},{"key":"2025123106463180000_15.8.e098371.33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bju.15756","article-title":"Guideline of guidelines: management of recurrent urinary tract infections in women","volume":"130 Suppl 3","author":"Kwok","year":"2022","journal-title":"BJU Int"},{"key":"2025123106463180000_15.8.e098371.34","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-020-1504-5","article-title":"The effectiveness of frequent antibiotic use in reducing the risk of infection-related hospital admissions: results from two large population-based cohorts","volume":"18","author":"van Staa","year":"2020","journal-title":"BMC Med"},{"key":"2025123106463180000_15.8.e098371.35","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c2096","article-title":"Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis","volume":"340","author":"Costelloe","year":"2010","journal-title":"BMJ"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-098371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:47:49Z","timestamp":1767192469000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-098371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,16]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjopen-2024-098371"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098371","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}